Raymond Debbane Portfolio
Invests via Siren, L.L.C. | Managed by Raymond Debbane
Invests via Siren, L.L.C.
Managed by Raymond Debbane
Automatically Tracked
Raymond Debbane Profile
Seasoned technology and fintech investor and operator, Raymond Debbane is focused on growth-stage software, payments and digital services. He combines operating experience leading cross-functional teams with investment-oriented portfolio construction, active board involvement, and strategic M&A support to drive scaling and exit value. Investment style emphasizes product-market fit, unit economics, and repeatable revenue models. Background blends technical and commercial disciplines and a track record of partnering with founders to professionalize operations and drive capital-efficient growth.
Seasoned technology and fintech investor and operator, Raymond Debbane is focused on growth-stage software, payments and digital services. He combines operating experience leading cross-functional teams with investment-oriented portfolio construction, active board involvement, and strategic M&A support to drive scaling and exit value. Investment style emphasizes product-market fit, unit economics, and repeatable revenue models. Background blends technical and commercial disciplines and a track record of partnering with founders to professionalize operations and drive capital-efficient growth.
Investment Philosophy & Strategy
Focuses on growth-stage software, payments and digital services with a bias toward businesses demonstrating clear product-market fit, repeatable revenue and strong unit economics. Allocates capital to companies where operational improvements and go-to-market rigor can materially accelerate scale; prefers active minority or board-backed positions to influence strategy, metrics and M&A timing. Investment horizon targets multi-year value creation through capital-efficient growth, disciplined downside protection, founder partnership and pragmatic exit planning.
Focuses on growth-stage software, payments and digital services with a bias toward businesses demonstrating clear product-market fit, repeatable revenue and strong unit economics. Allocates capital to companies where operational improvements and go-to-market rigor can materially accelerate scale; prefers active minority or board-backed positions to influence strategy, metrics and M&A timing. Investment horizon targets multi-year value creation through capital-efficient growth, disciplined downside protection, founder partnership and pragmatic exit planning.
Disclaimer: This Portfolio is derived from and computed based on publicly available data from SEC filings.
Gain and growth charts are calculated per selected timeframe:
143.18%
Gain +2.58%
Monthly
4.18%
Yearly
63.59%
Drawdown
43.26%
$4.31B
Equity
Holdings
$4.31B
Investment
$2.44B
$2.03B
Profit +$70.85M
Realized
$150.95M
Unrealized
$1.88B
Dividends
$699,957.18
Goals
Avg. 100% completed goals
Yearly
Gain > 5% 2026
Yearly
Gain < 20% 2026
Today
Compared To Yesterday
Gain
2.58%
Profit
$70.85M
Win %
66%
This Week
Compared To Last Week
Gain
-1.61%
Profit
-$70.49M
Win %
66%
This Month
Compared to last month
Gain
-0.17%
Profit
-$7.15M
Win %
66%
This Year
Compared to last year
Gain
24.87%
Profit
$859.2M
Win %
66%
AGEN Agenus Inc.
+16.4%
+$867,363.75 
PVLA Pavella Therapeutics Inc.
+15.16%
+$4.85M 
NBIS Nebius Group N.V.
+13.38%
+$2.78M 
AEVA Aeva Technologies, Inc.
+10.63%
+$185,900 
MU Micron Technology, Inc.
+10.17%
+$528,242.94 
RZLT Rezolute, Inc.
+8.57%
+$1.27M 
MANE Veradermics Inc.
+6.36%
+$10.14M 
GOSS Gossamer Bio Inc.
+6.17%
+$45,318.02 
TRVI Trevi Therapeutics Inc.
+5.84%
+$1.75M 
GENB Generate Biomedicines, Inc.
+5.67%
+$566,800.08 
TNGX Tango Therapeutics Inc.
+5.56%
+$8.66M 
AMLX Amylyx Pharmaceuticals, Inc. Common Stock
+4.7%
+$1.01M 
ORIC Oric Pharmaceuticals Inc.
+4.61%
+$1.44M 
IONQ IonQ, Inc.
+4.58%
+$266,900 
RAPP Rapport Therapeutics Inc.
+4.51%
+$1.16M 
IREN IREN Limited
+4.37%
+$75,640.5 
SYRE Spyre Therapeutics, Inc.
+4.24%
+$3.38M 
ZURA Zura Bio Ltd.
+4.09%
+$802,996.19 
IVVD Invivyd Inc.
+3.75%
+$102,800 
ARWR Arrowhead Pharmaceuticals Inc.
+3.6%
+$4.17M 
ELVN Enliven Therapeutics, Inc.
+3.52%
+$1.36M 
KRRO Korro Bio Inc.
+3.47%
+$138,635.17 
MPLT MapLight Therapeutics, Inc.
+3.44%
+$558,000 
DNLI Denali Therapeutics Inc.
+3.43%
+$1.1M 
RCUS Arcus Biosciences Inc.
+3.37%
+$2.86M 
SION Sionna Therapeutics Inc.
+3.37%
+$462,000 
TSLA Tesla, Inc.
+3.33%
+$264,449.78 
MNPR Monopar Therapeutics Inc.
+3.22%
+$920,805.25 
TSHA Taysha Gene Therapies Inc.
+3.14%
+$1.55M 
CGEM Cullinan Therapeutics, Inc.
+3.09%
+$644,441.4 
DMRA Damora Therapeutics, Inc.
+2.91%
+$864,090 
DYN Dyne Therapeutics Inc.
+2.86%
+$1.49M 
VTVT vTv Therapeutics Inc.
+2.72%
+$143,440 
FULC Fulcrum Therapeutics Inc.
+2.63%
+$223,720 
SEPN Septarna Inc.
+2.61%
+$1.68M 
DFTX Definium Therapeutics, Inc.
+2.48%
+$974,662.58 
GPCR Structure Therapeutics Inc.
+2.26%
+$1.41M 
CYTK Cytokinetics, Incorporated
+2.09%
+$1.02M 
RYTM Rhythm Pharmaceuticals Inc.
+2.09%
+$1.59M 
BCAX Bicara Therapeutics Inc.
+2.04%
+$3.22M 
AVGO Broadcom Inc.
+2.04%
+$115,650 
COGT Cogent Biosciences, Inc.
+2.02%
+$1.32M 
WVE Wave Life Sciences Ltd.
+2.01%
+$282,485 
OLMA Olema Pharmaceuticals Inc.
+1.85%
+$998,959.29 
FPS Forgent Power Solutions, Inc.
+1.84%
+$71,000 
EWTX Edgewise Therapeutics, Inc.
+1.75%
+$3.01M 
NVDA NVIDIA Corporation
+1.72%
+$311,797.5 
ENGN enGene Therapeutics Inc.
+1.63%
+$160,221.35 
MDLN Medline Inc.
+1.53%
+$14,875 
ERAS Erasca, Inc.
+1.38%
+$2.92M 
SLDB Solid Biosciences Inc.
+1.12%
+$730,588.47 
QURE uniQure N.V.
+1.11%
+$440,000 
NU Nu Holdings Ltd.
+1.07%
+$3,750 
SRRK Scholar Rock Holding Corporation
+1.03%
+$5.64M 
NMRA Neumora Therapeutics, Inc.
+0.92%
+$127,467.33 
SEER Seer, Inc.
+0.91%
+$45,731.32 
WHWK Whitehawk Therapeutics, Inc.
+0.75%
+$59,128.8 
ABSI Absci Corporation
+0.67%
+$99,000 
STOK Stoke Therapeutics Inc.
+0.61%
+$339,208.99 
XENE Xenon Pharmaceuticals Inc.
+0.55%
+$474,683.04 
IRON Disc Medicine Inc.
+0.48%
+$356,713.92 
RVMD Revolution Medicines Inc.
+0.44%
+$883,229.1 
KYMR Kymera Therapeutics Inc.
+0.42%
+$1.48M 
TENX Tenax Therapeutics Inc.
+0.32%
+$21,357.05 
AGMB Agomab Therapeutics NV
+0.25%
+$12,337.5 
LXRX Lexicon Pharmaceuticals, Inc.
+0.2%
+$208,226.53 
BCYC Bicycle Therapeutics plc American Depositary Receipt
+0.12%
+$7,804.41 
CRNX Crinetics Pharmaceuticals Inc.
+0.04%
+$57,109.08 
BEIGF BeiGene Ltd.
0%
$0 
CNTA Centessa Pharmaceuticals plc American Depositary Receipt
0%
$0 
MSLE Satellos Bioscience Inc.
0%
$0 
NBP NovaBridge Biosciences American Depositary Shares
0%
$0 
SLNCF Silence Therapeutics plc
0%
$0 
TSMWF Taiwan Semiconductor Manufacturing Company Limited
0%
$0 
FIG Figma Inc. Class A Common Stock
-7.95%
-$95,475 
KLRS Kalaris Therapeutics, Inc.
-6.75%
-$117,665.46 
FROG JFrog Ltd
-6.46%
-$752,285.44 
AS Amer Sports, Inc.
-4.55%
-$82,750 
DT Dynatrace, Inc.
-4.31%
-$288,750 
CRWD CrowdStrike Holdings, Inc.
-3.37%
-$617,353.2 
GTLB GitLab Inc.
-3.35%
-$114,000 
DBVT Dbv Technologies S.A. Sponsored ADR
-3.31%
-$895,805.69 
MNDY monday.com Ltd.
-3.22%
-$61,750 
WK Workiva Inc.
-3.11%
-$164,650 
DDOG Datadog, Inc. Class A Common Stock
-2.44%
-$349,149.54 
CTMX CytomX Therapeutics Inc.
-2.3%
-$280,074.59 
NOW ServiceNow, Inc.
-2.06%
-$187,678.95 
TBLA Taboola.com Ltd.
-2.01%
-$1.07M 
CLBT Cellebrite DI Ltd.
-1.98%
-$95,020.92 
RANI Rani Therapeutics Holdings Inc.
-1.86%
-$25,600 
ANNX Annexon, Inc.
-1.53%
-$336,484.91 
BEKE Ke Holdings Inc. ADR
-1.5%
-$25,500 
PDD PDD Holdings Inc. American Depositary Shares
-1.22%
-$87,571.05 
GOOGL Alphabet Inc
-1.18%
-$272,667.45 
PRMB Primo Brands Corp. Common Stock
-1.13%
-$13,750 
MSFT Microsoft Corp.
-0.89%
-$148,140.4 
AMZN Amazon.com Inc
-0.8%
-$93,515.21 
FHTX Foghorn Therapeutics Inc.
-0.45%
-$16,936.92 
RELY Remitly Global, Inc.
-0.34%
-$123,461.68 
IKT Inhibikase Therapeutics Inc.
-0.31%
-$40,365 Events
Loading...
Dividends
Dividend Analysis
Loading...
No Data
| Trades 536 | Longs Won 259/536 48% | Profit Factor 4.75 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $22.44M |
| Average Win $9.93M | Best Trade (Jul 19) $414.86M | Sharpe Ratio -50.04 |
| Average Loss -$1.96M | Worst Trade (Sep 29) -$50.2M | Z-Score 1.97 (95.16%) |
| Commissions $0 | Avg. Trade Length 9m 1w 5d | Expectancy $3.79M |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | 0.11% |
| Consecutive Losing Trades | 2,208 | 1,987 | 1,766 | 1,545 | 1,325 | 1,104 | 883 | 662 | 442 | 221 |
Hover over the desired column for a detailed explanation.
Returns
Overall, MonthlyNo Data
Option values are updated at end of day.
No Data
No Data
Option values are updated at end of day.
No Data
No Data
No Data
No Data
FAQ
Which stocks have generated the highest profits for Raymond Debbane?
The largest contributions to the portfolio's profits come from the following stocks: Centessa Pharmaceuticals plc American Depositary Receipt - $73.32M, Scholar Rock Holding Corporation - $70.75M, Arrowhead Pharmaceuticals Inc - $53.45M, Tango Therapeutics Inc - $32.92M, and Wave Life Sciences Ltd - $19.18M. These positions have been the main drivers of growth and have significantly impacted the investor's overall performance.
Which stocks have generated the largest losses for this investor?
The largest losses in the portfolio are associated with the following stocks: Igm Biosciences Inc - $51.35M, Lexicon Pharmaceuticals, Inc - $39.27M, Vaxcyte, Inc - $24.5M, Vera Therapeutics Inc - $15.8M, and Kura Oncology Inc - $14.51M. These positions have had the most negative impact on overall performance and highlight the weaker areas of the portfolio.
What dividends does Raymond Debbane's portfolio generate?
The portfolio generates substantial dividend income, with a total of $699,957.18 earned over time. The largest contributors to dividend income include Taiwan Semiconductor Manufacturing Company Limited - $162,728.27, Microsoft Corp - $141,321.8, QUALCOMM Incorporated - $75,340, Alphabet Inc - $48,150.18, and Salesforce Inc - $38,854.4. This indicates that dividends play a meaningful role in the investor's overall strategy.
How stable are Raymond Debbane's monthly returns?
Raymond Debbane's monthly returns look highly volatile. The portfolio shows large month-to-month swings, and the broader risk profile suggests that performance can change sharply over short periods. This kind of pattern may suit users who are comfortable with significant fluctuations, but it is less likely to appeal to those who prefer steadier and more predictable results.
Can Raymond Debbane's strategy be considered aggressive or moderate?
Raymond Debbane's strategy can be considered aggressive. The combination of high drawdowns, elevated volatility, and/or concentrated positions suggests a willingness to accept significant risk in pursuit of higher long-term returns. This approach is generally more suitable for users who are comfortable with large fluctuations in portfolio value.
Should beginners follow Raymond Debbane's strategy?
Raymond Debbane's strategy is unlikely to be suitable for beginners. The portfolio shows signs of high risk, significant volatility, or structural complexity, which can make it difficult to follow and potentially stressful for less experienced users. This type of approach is generally better suited to more advanced investors.
